BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL

CLINICAL AND PHARMACOLOGICAL PRINCIPLES OF DRUG ADMINISTRATION IN NEONATES AND YOUNG CHILDREN: AN ONTOGENETIC PERSPECTIVE

Khasanov Zakir Khushbokovich
Shurchi Abu Ali ibn Sina Public Health Technical College Senior Lecturer, Department of Pharmaceutical Sciences
Doi: https://doi.org/10.5281/zenodo.24223937

Abstract:

Background: Pharmacotherapy in neonates and early childhood differs fundamentally from adult clinical protocols due to dynamic physiological and biochemical ontogeny. Functional immaturity of hepatic enzyme systems, renal clearance, and blood-brain barrier permeability profoundly alters drug disposition, increasing the risk of subtherapeutic exposure or severe iatrogenic toxicity when adult doses are linearly extrapolated.

Objective: This narrative review synthesizes contemporary clinical-pharmacological evidence regarding: (1) age-dependent alterations in drug absorption, distribution, metabolism, and excretion (ADME ontogeny); and (2) individualized dosing strategies, excipient safety, rational antimicrobial stewardship, and model-informed precision dosing (TDM and PBPK) in pediatric populations.

Methods: A structured narrative review was conducted analyzing peer-reviewed clinical pharmacology studies, pharmacometric modeling reviews, and international regulatory guidelines (FDA, ICH E11A, EMA, WHO) retrieved from PubMed/MEDLINE, Scopus, and ScienceDirect covering the period from 2007 to 2026.

Results: Neonatal ontogeny is characterized by near-neutral gastric pH, elevated total body water (75–85%), reduced plasma albumin levels, immature Phase I (CYP3A4, CYP1A2) and Phase II (UGT) hepatic enzymes, and low glomerular filtration rates (25–40% of adult values). Consequently, hydrophilic drugs require higher loading doses per kilogram, whereas renally cleared and glucuronidated medications demand extended dosing intervals. Furthermore, pharmaceutical excipients such as benzyl alcohol and propylene glycol pose life-threatening metabolic risks in neonates.

Conclusion: Safe and effective pediatric pharmacotherapy requires abandoning simple weight-based linear scaling in favor of individualized dosing frameworks anchored in postmenstrual age (PMA), organ maturation, excipient screening, therapeutic drug monitoring (TDM), and physiologically based pharmacokinetic (PBPK) modeling.

Keywords: Neonatal pharmacology; Pediatric pharmacotherapy; Pharmacokinetic ontogeny; Individualized dosing; Therapeutic drug monitoring (TDM); PBPK modeling; Excipient toxicity; Medication safety.

1. Introduction

Ensuring effective, evidence-based, and safe pharmacotherapy for neonates and young children remains a top priority in contemporary clinical pharmacology and pediatric healthcare. As recognized by the World Health Organization (WHO) and international regulatory agencies, pediatric patients—particularly neonates—are not merely "small adults." During the first months

and years of life, every organ system undergoes rapid morphological and functional maturation (ontogeny).

In the neonatal period, especially among preterm infants, hepatic microsomal enzyme activity, renal clearance, gastrointestinal motility and secretory function, plasma protein concentrations (albumin and α1-acid glycoprotein), and blood-brain barrier (BBB) permeability differ substantially from those of adults. These factors directly alter the pharmacokinetic profile, elimination half-life (T1/2), and therapeutic window of administered medications.

In clinical practice, linear (proportional) scaling of adult doses based solely on body weight frequently results in either subtherapeutic exposure or drug accumulation (cumulation) leading to severe toxicity. Historical and contemporary pharmacovigilance data demonstrate that iatrogenic drug complications in neonates (such as chloramphenicol-induced "gray baby syndrome" or benzyl alcohol-associated metabolic acidosis) largely stem from overlooking ontogenetic characteristics.

Between 2022 and 2026, the U.S. Food and Drug Administration (FDA), the International Council for Harmonisation (ICH E11A), and leading clinical pharmacologists established updated regulatory and scientific frameworks for neonatal clinical studies and model-informed precision dosing (MIPD).

2. Materials and Methods

This manuscript was prepared as a narrative review based on a comprehensive synthesis of peer-reviewed scientific literature and international clinical-pharmacological regulatory guidelines.

Literature Search Strategy: Relevant publications were retrieved from PubMed/MEDLINE, Scopus, ScienceDirect, and Google Scholar covering the period from 2007 to 2026. Search queries combined the following keywords: "neonatal clinical pharmacology", "pediatric pharmacokinetics", "ontogeny of drug metabolism", "individualized dosing in neonates", "therapeutic drug monitoring", and "PBPK modeling in children".

Inclusion and Exclusion Criteria: Studies and official regulatory guidelines (FDA, EMA, WHO, ICH) addressing pharmacokinetics, pharmacodynamics, dosing algorithms, and excipient safety in neonates and early childhood were included. Publications restricted exclusively to adult populations or lacking clinical-pharmacological substantiation were excluded.

Analytical Approach: Selected sources were evaluated using comparative analysis, systematization, and clinical-pharmacological synthesis.

3. Results and Discussion

3.1. Pediatric Age Classification and Physiological Ontogeny

In clinical pharmacology, pediatric patients are strictly stratified by developmental stages, each characterized by distinct metabolic and excretory capacities:

- **Preterm neonates:** Gestational age (GA) < 37 completed weeks;
- **Term neonates:** Postnatal age 0–27 days;

- **Infants and toddlers:** 28 days to 23 months;
- **Early childhood:** 2 to 5 years.

To ensure dosing precision, three standardized age metrics are utilized: gestational age (GA)—time elapsed from the first day of the last menstrual period to birth; postnatal age (PNA)—chronological time elapsed after birth; and postmenstrual age (PMA)—the sum of GA and PNA (PMA = GA + PNA). PMA serves as the most reliable clinical indicator of hepatic and renal maturation.

3.2. Age-Dependent Alterations in Pharmacokinetics (ADME Ontogeny)

The disposition of a drug within the body—Absorption, Distribution, Metabolism, and Excretion (ADME)—undergoes profound maturational shifts during early life (Table 1).

Table 1. Age-Dependent Pharmacokinetic Characteristics and Clinical Implications in Neonates and Young Children

Pharmacokinetic Stage	Physiological & Biochemical Characteristics	Pharmacological & Clinical Implications
Absorption	• Near-neutral gastric pH (pH 6–8 during the first days of life); • Delayed gastric emptying and irregular intestinal peristalsis; • Reduced bile acid and pancreatic enzyme secretion; • Thin stratum corneum, high skin hydration, and high body surface area-to-weight ratio.	• Increased bioavailability of acid-labile drugs (e.g., penicillins); • Delayed absorption of weak acids (e.g., phenobarbital); • Reduced absorption of lipophilic drugs and fat-soluble vitamins; • Rapid systemic absorption of topical agents, increasing the risk of systemic toxicity.
Distribution	• High total body water (~80–85% in preterm neonates, ~75% in term neonates vs. ~60% in adults); • Low adipose tissue proportion (~12–15%); • Lower plasma albumin and α1-acid glycoprotein levels, plus competitive binding with endogenous bilirubin; • Increased blood-brain barrier (BBB) permeability.	• Larger volume of distribution (Vd) for hydrophilic drugs (aminoglycosides, vancomycin), requiring higher loading doses; • Smaller Vd for lipophilic drugs; • Increased unbound (pharmacologically active) fraction of protein-bound drugs (phenytoin, diazepam); • Risk of bilirubin displacement by drugs like ceftriaxone, elevating the risk of kernicterus.
Metabolism	• Low activity of Phase I enzymes (CYP3A4, CYP1A2, CYP2C9); predominance of fetal CYP3A7;	• Prolonged elimination half-life (T1/2) and slower clearance of many drugs (caffeine, theophylline, diazepam);

	• Immaturity of Phase II conjugation enzymes (especially UDP-glucuronosyltransferase — UGT); • Relatively well-developed sulfation pathways.	• Toxic accumulation of drugs reliant on glucuronidation (chloramphenicol, morphine); • Relatively safe clearance of paracetamol via compensatory sulfation.
Excretion	• Neonatal glomerular filtration rate (GFR) is only 25–40% of adult values (maturing fully by 1–2 years of age); • Immature renal tubular secretion and reabsorption.	• Reduced clearance of renally eliminated drugs (gentamicin, amikacin, cephalosporins, digoxin); • Necessity for extended dosing intervals (e.g., every 24–36 hours).

3.3. Pharmacodynamic Characteristics and Receptor Sensitivity

Pharmacodynamics governs the interaction between a drug and its target receptors and the resulting physiological response. In pediatric populations, receptor density, binding affinity, and downstream signaling pathways are actively developing:

- **Central Nervous System (CNS):** Due to the developmental state of the GABAergic system in neonates, sedatives and anticonvulsants (phenobarbital, benzodiazepines) may elicit paradoxical excitation or prolonged sedation. Opioid analgesics (morphine, fentanyl) induce more pronounced respiratory depression in neonates than in adults.
- **Cardiovascular and Respiratory Systems:** Incomplete sympathetic innervation of the neonatal myocardium alters sensitivity to inotropic and vasopressor agents (dopamine, dobutamine), requiring careful hemodynamic titration.

3.4. Principles of Individualized Pediatric Dosing

Several quantitative methods are employed in pediatric pharmacotherapy depending on the clinical context:

1. Weight-Based Dosing (mg/kg): The most widely used approach: Single Dose (mg) = Body Weight (kg) × Recommended Dose (mg/kg). Clinical Note: For instance, if a clinical guideline specifies a single dose of 10 mg/kg, a child weighing 5 kg requires 50 mg. However, in obese children, ideal body weight (IBW) should be considered for hydrophilic drugs, while neonatal dosing must integrate GA and PNA adjustments.

2. Body Surface Area (BSA) Dosing (mg/m²): Preferred for narrow-therapeutic-index agents (e.g., antineoplastic chemotherapy, certain antivirals), as cardiac output, GFR, and basal metabolic rate correlate closely with BSA.

3. Allometric Scaling: A pharmacometric approach grounded in the principle that basal metabolic clearance scales to body weight raised to the 0.75 power, combined with a maturation function (Fmat): CL_child = CL_adult × (Weight_child / 70 kg)^0.75 × F_mat(PMA).

3.5. Medication Safety, Excipient Toxicity, and Measurement Errors

Adverse drug reactions (ADRs) in young children are frequently triggered not only by active pharmaceutical ingredients (APIs) but also by inactive formulation components—excipients (Table 2).

Table 2. Pharmaceutical Excipients Requiring Caution in Neonatal and Pediatric Formulations

Excipient	Common Dosage Forms	Potential Clinical Risks in Neonates
Benzyl alcohol	Preservative in parenteral solutions	"Gasping syndrome," severe metabolic acidosis, intraventricular hemorrhage, and mortality (due to immature alcohol dehydrogenase).
Propylene glycol	Solvent in oral and intravenous formulations	Hyperosmolality, lactic acidosis, CNS depression, and renal tubular toxicity.
Ethanol	Oral liquid solutions and elixirs	Hypoglycemia, CNS depression, and neurotoxicity (strictly restricted by WHO and EMA).
Parabens (methyl-, propylparaben)	Preservatives in oral suspensions and syrups	Displacement of bilirubin from albumin binding sites, increasing the risk of hyperbilirubinemia.
Sorbitol and fructose	Sweeteners in pediatric syrups	Osmotic diarrhea, abdominal colic, and severe hypoglycemia in hereditary fructose intolerance.

Prevention of Measurement and Dosing Errors: A major technical error in pediatric practice involves confusing milligrams (mg) with milliliters (ml) or utilizing household spoons (whose volume varies from 2.5 ml to 7 ml). Consequently, all oral liquid medications must be administered exclusively using calibrated oral syringes.

3.6. Clinical-Pharmacological Principles of Antimicrobial Therapy

Antibiotics represent the most frequently prescribed drug class in neonatal sepsis and pediatric infections. Rational antimicrobial stewardship relies on:

- Confirming bacterial infection probability using clinical criteria and biomarkers (C-reactive protein, procalcitonin, blood cultures);
- Selecting empirical regimens based on likely pathogens (e.g., ampicillin plus gentamicin for early-onset neonatal sepsis);

- Avoiding ceftriaxone in neonates—particularly those with hyperbilirubinemia or receiving calcium-containing intravenous solutions—due to the risk of fatal calcium-ceftriaxone precipitation in the lungs and kidneys;
- Implementing antimicrobial de-escalation once microbiological susceptibility results are obtained and avoiding unnecessarily prolonged courses.

3.7. Contemporary Precision Dosing: TDM and PBPK Modeling

Recent advancements (2024–2026) in neonatal and pediatric intensive care highlight three transformative precision-dosing methodologies:

1. Therapeutic Drug Monitoring (TDM): Measuring plasma concentrations of narrow-therapeutic-index drugs (gentamicin, amikacin, vancomycin, phenobarbital, caffeine) to individualize subsequent doses, thereby minimizing nephrotoxicity and ototoxicity.

2. Population Pharmacokinetics (PopPK): Utilizing sparse blood sampling across large neonatal cohorts to develop mathematical dosing nomograms incorporating PMA, body weight, and serum creatinine.

3. Physiologically Based Pharmacokinetic (PBPK) Modeling: Integrating organ volumes, blood flow rates, and enzyme ontogeny into virtual mechanistic models to predict safe starting doses prior to pediatric clinical trials, as endorsed by the ICH E11A guideline.

4. Practical Pharmaceutical Recommendations

To safeguard medication use in neonates and young children, healthcare professionals and pharmacists should implement the following measures:

1. Comprehensive Anthropometric Documentation: Every prescription and medication order must explicitly record current body weight (kg), gestational age (GA), postnatal age (PNA), and postmenstrual age (PMA).

2. Independent Double-Check Verification: Doses for high-alert medications (antibiotics, anticonvulsants, cardiac glycosides, vasoactive agents) should undergo independent double-checking by a physician and a clinical pharmacist or nurse.

3. Standardized Oral Measuring Devices: Clinicians and caregivers must use calibrated oral syringes with millimeter graduations and verify formulation concentrations (mg/5 ml or mg/ml) prior to every administration.

4. Excipient Screening: Neonatal units should restrict formulations containing benzyl alcohol, propylene glycol, or high concentrations of ethanol.

5. Renal and Hepatic Function Monitoring: When administering nephrotoxic or hepatotoxic agents, serum creatinine, urine output, and hepatic transaminases must be monitored regularly alongside TDM where available.

6. Active Pharmacovigilance: Establish institutional protocols for the prompt reporting of suspected ADRs and medication errors to national pharmacovigilance centers.

5. Limitations and Future Perspectives

As a narrative review, this article synthesizes existing international clinical evidence and regulatory guidance rather than presenting original experimental clinical trial data. Future research directions should prioritize conducting regional population pharmacokinetic (PopPK) studies on commonly prescribed pediatric antibiotics and anticonvulsants, as well as integrating automated, PMA-adjusted clinical decision support calculators into electronic health record systems.

6. Conclusion

Pharmacotherapy in neonates and young children differs fundamentally from adult treatment protocols due to dynamic physiological and biochemical ontogeny. The gradual maturation of hepatic enzyme systems and renal excretory capacity, elevated total body water ratios, and distinct plasma protein binding profiles govern pediatric pharmacokinetic and pharmacodynamic responses.

Achieving optimal therapeutic efficacy with minimal risk requires abandoning simple linear weight-based extrapolation from adult doses in favor of individualized dosing frameworks anchored in postmenstrual age, body weight, organ maturation, excipient safety, and therapeutic drug monitoring (TDM). Integrating population and physiologically based pharmacokinetic (PBPK) modeling into clinical practice represents a major milestone toward precision medicine in pediatrics.

References

1. Allegaert K, Yalcin N, Flint RB, Simons SHP. Neonatal Clinical Pharmacology. Children. 2024;11(9):1102. doi:10.3390/children11091102.
2. Shaniv D, Allegaert K. Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection. Archives of Disease in Childhood – Education and Practice Edition. 2024;109(5):234–241. doi:10.1136/archdischild-2023-326325.
3. U.S. Food and Drug Administration (FDA). General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products: Guidance for Industry. Silver Spring, MD: FDA; July 2022.
4. International Council for Harmonisation (ICH). ICH Harmonised Guideline E11A: Pediatric Extrapolation. Final Step 4 Version; December 2024.
5. Staub E, Bolisetty S, Allegaert K, Raaijmakers A. Neonatal Kidney Function, Injury and Drug Dosing: A Contemporary Review. Children. 2025;12(3):339. doi:10.3390/children12030339.
6. Rodríguez-Báez AS, Kreuzberger N, Iannizzi C, et al. Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review. Clinical Pharmacokinetics. 2026;65(11):1629–1666. doi:10.1007/s40262-026-01670-0.
7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology — drug disposition, action, and therapy in infants and children. New England Journal of Medicine. 2003;349(12):1157–1167.
8. Tibbetts E. Pharmacokinetics in Children. MSD Manual Professional Edition. Updated July 2025.
9. U.S. Food and Drug Administration (FDA). General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products: Guidance for Industry. Silver Spring, MD: FDA; September 2022.

10. World Health Organization (WHO). Promoting Safety of Medicines for Children. Geneva: WHO Press; 2007.
11. European Medicines Agency (EMA). Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. London: EMA; 2009.
12. Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacological Research. 2011;63(5):362–365.